作者：金杜律师事务所医疗法律事务组
现行有效的法律法规虽然已对制药企业产品推广作出了规定，但是大部分的规定以定性为主。RDPAC药品推广行为准则(2012年修订版)(“《行为准则》”)进一步细化并明确了药品推广过程中的相关要求与标准，并试图建立一些明确、清晰的界限的行业规范。
Continue Reading RDPAC药品推广行为准则(2012年修订版)
The promotion of private healthcare services- A Challenge or an opportunity?
By Kalley Chen King & Wood Mallesons’ Securities Group
To address China’s aging population issue as well as its need to improve access to healthcare in rural areas, healthcare reform has become a priority for the Chinese government.
A key mechanism to improve access is through the promotion of private healthcare. While current exit restrictions exist in relation to private medical institutions, recent policy developments which have liberalized investment in the healthcare sector demonstrate China’s progress toward improving healthcare. It is likely that these policies may stimulate greater PE investment opportunities, in particular within the private healthcare sector.
Continue Reading The promotion of private healthcare services- A Challenge or an opportunity?
大力发展私营医疗服务：挑战还是机会？
为了解决中国人口老龄化问题，同时改善农村地区医疗水平，医疗改革已经成为中国政府优先关注的问题。
发展私营医疗产业是提升医疗水平的一个主要机制。虽然私营医疗机构目前存在退出限制，但是政府近期颁布的一系列新政，使得医疗健康领域的投资更加开放，显示了中国在提升医疗服务水平方面的进展。这些政策很可能促进更多的私募投资机会，特别是私营医疗服务领域。
Continue Reading 大力发展私营医疗服务：挑战还是机会？
Proposed Change on Medical Advertisement Related Regulation Might Cease All Advertisement for Otc Medicines in Public Media
By King & Wood Mallesons’ Healthcare Group
Some recent news releases show that the PRC Ministry of Health has proposed to revise (the “Proposed Revision”) the current Measures for Inspection of Medical Advertisement (promulgated on 13 March 2007 and effective as of 1 May 2007) (the “2007 Measures”).
Among all other changes in the Proposed Revision, one hot-button issue is that, except for general information and name of the medicine, any other specific information (e.g. usage) regarding all medicine, including OTC medicines, is no longer allowed in public-oriented media, and only allowed in professional media. Compared with the 2007 Measures, which allowed OTC medicine advertisement to be used in public media, but subject to inspection by the SFDA. However, the Proposed Revision might ban this practice.
Continue Reading Proposed Change on Medical Advertisement Related Regulation Might Cease All Advertisement for Otc Medicines in Public Media
所有对非处方药品的大众媒体广告宣传将可能因药品广告有关法规的修订而终止
作者：金杜律师事务所医疗法律事务组
近期发布的消息显示，中国卫生部已计划对现行有效的于2007年3月13日发布并于2007年5月1日生效的《药品广告审查办法》(“2007年办法”)进行修订并透露了部分修订意见(“修订意见”)。
在修订意见的所有修改中，一个热点在于除药品名称和一般信息外，禁止就所有药品包括非处方药品(OTC药品)的任何特定信息(如，使用方法)进行以公众为对象的广告宣传，而仅能在专业媒体上进行广告宣传。与2007年办法相比较，非处方药品曾可以公众媒体进行广告宣传，但是需要受限于国家食品药品监督管理局的审查。然而，在修订意见中可能完全禁止该类广告。
Continue Reading 所有对非处方药品的大众媒体广告宣传将可能因药品广告有关法规的修订而终止